295 related articles for article (PubMed ID: 19808740)
21. [Therapy of multiple sclerosis].
Simó M
Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
[TBL] [Abstract][Full Text] [Related]
22. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial.
Wolansky LJ; Haghighi MH; Sevdalis E; Cook SD; Sethi N; Liu J; Joseph G; Tulloch K; Cadavid D
J Neuroimaging; 2005 Jul; 15(3):289-90. PubMed ID: 15951416
[No Abstract] [Full Text] [Related]
23. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
Thrower BW
Neurology; 2007 Jun; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
[TBL] [Abstract][Full Text] [Related]
24. Editorial: the pitfalls of combination therapy.
Vermersch P
Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
[No Abstract] [Full Text] [Related]
25. Interferon beta in multiple sclerosis: how much BENEFIT?
Pittock SJ
Lancet; 2007 Aug; 370(9585):363-4. PubMed ID: 17678997
[No Abstract] [Full Text] [Related]
26. Solving the MS puzzle.
Hobson K
US News World Rep; 2002 Oct; 133(13):60-2. PubMed ID: 12375480
[No Abstract] [Full Text] [Related]
27. [Clinical surveillance of patients with multiple sclerosis].
Cazzato G; Zorzon M
Recenti Prog Med; 2003 Apr; 94(4):173-6. PubMed ID: 12677789
[TBL] [Abstract][Full Text] [Related]
28. A practical approach to immunomodulatory therapy for multiple sclerosis.
Burks JS
Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
[TBL] [Abstract][Full Text] [Related]
29. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
[TBL] [Abstract][Full Text] [Related]
30. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo].
Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A
Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317
[No Abstract] [Full Text] [Related]
31. [Status and perspective in the therapy of multiple sclerosis. C. Prevention of relapses and of progression].
Pöhlau D
Krankenpfl J; 1997 Mar; 35(3):69-71. PubMed ID: 9136384
[No Abstract] [Full Text] [Related]
32. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
Giacomini PS; Arnold DL; Bar-Or A; Antel JP
Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
[No Abstract] [Full Text] [Related]
33. [Treatment with beta-interferon should be started already after the first attack of MS].
Söderström M
Lakartidningen; 2001 Feb; 98(6):587-90, 593-4. PubMed ID: 11475246
[No Abstract] [Full Text] [Related]
34. Use of interferon-beta in the treatment of multiple sclerosis.
Derwenskus J; Lublin FD
Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
[No Abstract] [Full Text] [Related]
35. Interferon beta-1a during a first demyelinating event.
Esmonde TF
N Engl J Med; 2001 Jan; 344(3):229; author reply 229-30. PubMed ID: 11188841
[No Abstract] [Full Text] [Related]
36. Approaches to neuroprotective strategies in multiple sclerosis.
Tselis A; Khan OA; Lisak RP
Expert Opin Pharmacother; 2010 Dec; 11(17):2869-78. PubMed ID: 20687779
[TBL] [Abstract][Full Text] [Related]
37. Summary: Registry data.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S39-41. PubMed ID: 21205682
[No Abstract] [Full Text] [Related]
38. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
Oger J; Freedman M
Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197
[No Abstract] [Full Text] [Related]
39. [Disease-modifying treatments in multiple sclerosis].
Confavreux C; Bouhour F; Vukusic S
Rev Prat; 1999 Nov; 49(17):1882-9. PubMed ID: 10598505
[TBL] [Abstract][Full Text] [Related]
40. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
Pöllmann W; Erasmus LP; Feneberg W; Straube A
Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
